L’hôpital de Rangueil est un établissement public de santé situé en France à Toulouse Haute-Garonne quartier de Rangueil sur le Pech-David. Il fait partie du centre hospitalier universitaire de Toulouse.

During the past decade, CHU Rangueil conducted 161 clinical trials. In the 10-year time frame, 161 clinical trials started and 43 clinical trials were completed, i.e. on average, 26.7% percent of trials that started reached the finish line to date. In the past 5 years, 80 clinical trials started and 24 clinical trials were completed. i.e. 30% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Rangueil" #1 sponsor was "University Hospital, Toulouse" with 16 trials, followed by "Boston Scientific Corporation" with 15 trials sponsored, "Ipsen" with 14 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 9 trials sponsored and "Institut Claudius Regaud" with 9 trials sponsored. Other sponsors include 203 different institutions and companies that sponsored additional 123 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Rangueil" #1 collaborator was "Ministry of Health, France" with 5 trials as a collaborator, "Abbott" with 3 trials as a collaborator, "Biocompatibles UK Ltd" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator and "Roche Pharma AG" with 3 trials as a collaborator. Other collaborators include 96 different institutions and companies that were collaborators in the rest 98 trials.

According to Clinical.Site data, the most researched conditions in "CHU Rangueil" are "Coronary Artery Disease" (19 trials), "Ulcerative Colitis" (10 trials), "Heart Failure" (8 trials), "Crohn's Disease" (6 trials) and "Acute Coronary Syndrome" (5 trials). Many other conditions were trialed in "CHU Rangueil" in a lesser frequency.

Most popular intervention types in "CHU Rangueil" are "Drug" (119 trials), "Device" (79 trials), "Other" (39 trials), "Procedure" (29 trials) and "Biological" (23 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (41 trials), "Botulinum toxin type A" (6 trials), "Filgotinib" (4 trials), "Cyclophosphamide" (3 trials) and "Daratumumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "CHU Rangueil" are 251 trials for "All" genders, 10 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are 82 active trials in "CHU Rangueil". 2 are not yet recruiting, 50 are recruiting, 29 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 148 completed trials in CHU Rangueil, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Rangueil, 5 "Phase 1" clinical trials were conducted, 50 "Phase 2" clinical trials and 79 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 13 trials, and there were also 73 trials that are defined as “Not Applicable".